Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents ...

Study cohort began collecting data on newborns through adulthood, and may offer objective clues on asthma and COPD disease ...

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active ...

It forecasts that the repurchases - which are due to complete in 18 months - will boost core earnings by 6% to 8% in 2025 ...

A new national survey of Canadian adults reveals significant gaps in understanding of shingles risk factors and a lack of ...

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has ...

The company posted a multifold jump per cent in consolidated net profit to Rs 230 crore as compared to Rs 46 crore a year ago ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand ...

GlaxoSmithKline Pharmaceuticals shares surged 20% to ₹2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, Arizona lawsuit says ...

GlaxoSmithKline Pharmaceuticals reported a significant increase in net profit to Rs 229 crore for the third quarter ending ...